NCCN Guidelines for Patients® | Chronic Myelogenous Leukemia - page 23

23
NCCN Guidelines for Patients
®
: Chronic Myelogenous Leukemia
Version 1.2014
Par t 7
Par t 6
Par t 5
Par t 4
Par t 3
Par t 2
Par t 1
3.2 Accelerated phase
Table 2. Criteria for accelerated phase
MD Anderson
1
World Health Organization
2
≥15% blasts in peripheral blood
10% to 19% blasts in peripheral blood and/or bone marrow
≥30% blasts and promyelocytes in peripheral blood ≥20% basophils in peripheral blood
≥20% basophils in peripheral blood
Very high or very low platelet count that is unrelated to treatment
Very low platelet count that is unrelated to treatment
Increasing spleen size and white blood cell count despite treatment
New chromosome changes (mutations)
New chromosome changes (mutations)
1 Adapted, with permission, from Faderl S, et al. Chronic myelogenous leukemia: Biology and therapy.
Ann Intern Med
1999; 131:207-219.
The American College of Physicians-American Society of Internal Medicine is not responsible for the accuracy of the translation.
2 Adapted from Swerdlow SH, Campo E, Harris NL, et al. (Eds.):
WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.
Lyon, France: IARC Press; 2008.
1...,13,14,15,16,17,18,19,20,21,22 24,25,26,27,28,29,30,31,32,33,...100
Powered by FlippingBook